Author details

Full Name

Elizabeth A Mullen

Affiliation

ORCID

Career Start Year

2001

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37902955	Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.	Cancer	2024
37848532	Hallmark discoveries in the biology of Wilms tumour.	Nat Rev Urol	2024
37933882	Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5.	Cancer	2024
36993649	The Genetic and Epigenetic Features of Bilateral Wilms Tumor Predisposition: A Report from the Children's Oncology Group AREN18B5-Q Study.	Res Sq	2023
37477907	Children's Oncology Group's 2023 blueprint for research: Renal tumors.		2023
37218455	Tolerability of ifosfamide-containing regimen in patients with high-risk renal and INI-1-deficient tumors.		2023
37343199	Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy.	J Clin Oncol	2023
36693221	Late Health Outcomes Among Survivors of Wilms Tumor Diagnosed Over Three Decades: A Report From the Childhood Cancer Survivor Study.	J Clin Oncol	2023
35072864	Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis: A Report from the Children's Oncology Group Study AREN0534.	Ann Surg Oncol	2022
35580298	Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533.	Journal of Clinical Oncology	2022
35383900	Outcomes based on histopathologic response to preoperative chemotherapy in children with bilateral Wilms tumor: A prospective study (COG AREN0534).	Cancer	2022
35617957	Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study.	Cell Rep Med	2022
35276672	Authors' Reply to the Letter to the Editor by Daniel M. Green.	J Natl Compr Canc Netw	2022
35076770	ASO Video Abstract: Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis-A Report from the Children's Oncology Group Study AREN0534.	Ann Surg Oncol	2022
34416705	Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor.	J Natl Compr Canc Netw	2021
34261517	Haplotype-resolved germline and somatic alterations in renal medullary carcinomas.	Genome Med	2021
32686305	The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor.	Pediatr Blood Cancer	2020
32267967	Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: A report from Children's Oncology Group study AREN03B2.	Cancer	2020
32134700	Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study.	J Clin Oncol	2020
32122923	Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers.	Clinical Cancer Research	2020
32160052	Imaging Characteristics of Nephrogenic Rests Versus Small Wilms Tumors: A Report From the Children's Oncology Group Study AREN03B2.	AJR Am J Roentgenol	2020
32089177	50 Years Ago in TheJournal ofPediatrics: 50 years of progress in renal cell carcinoma: From case reports to targeted therapy.	Journal of Pediatrics	2020
32459384	Results of Treatment for Patients With Multicentric or Bilaterally Predisposed Unilateral Wilms Tumor (AREN0534): A report from the Children's Oncology Group.	Cancer	2020
32926409	A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children's Oncology Group AREN0321 study.	Cancer	2020
31391345	Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor.	JCI Insight	2019
30287223	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.	Clin Genitourin Cancer	2019
30875281	Reply to L. Xie et al.	Journal of Clinical Oncology	2019
30860482	Renal medullary carcinomas depend upon <i>SMARCB1</i> loss and are sensitive to proteasome inhibition.	Elife	2019
31449468	Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.	J Clin Oncol	2019
31325873	Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study.	Eur J Cancer	2019
29211618	Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.	J Clin Oncol	2018
30027144	Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors.	JCO Precis Oncol	2018
30212299	Reply to D.M. Green.	Journal of Clinical Oncology	2018
30335557	Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.	Journal of Clinical Oncology	2018
29905933	The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing.	Cancer	2018
29659330	Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.	J Clin Oncol	2018
29613833	Reply to B. Zhang et al.	J Clin Oncol	2018
27811504	Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.	Ann Surg	2017
28689245	Imaging of renal medullary carcinoma in children and young adults: a report from the Children's Oncology Group.	Pediatr Radiol	2017
28504702	PGBD5 promotes site-specific oncogenic mutations in human tumors.	Nat Genet	2017
28951624	Erratum: PGBD5 promotes site-specific oncogenic mutations in human tumors.	Nat Genet	2017
28795993	Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group.	Ann Surg	2017
28697319	Renal Medullary Carcinoma: Establishing Standards in Practice.	J Oncol Pract	2017
27862952	Synchronous occurrence of acute lymphoblastic leukemia and wilms tumor in two patients: underlying etiology and combined treatment plan.	Pediatr Blood Cancer	2017
26772403	Pediatric cystic nephromas: distinctive features and frequent DICER1 mutations.	Hum Pathol	2016
27229358	Surgical protocol violations in children with renal tumors provides an opportunity to improve pediatric cancer care: a report from the Children's Oncology Group.	Pediatr Blood Cancer	2016
27400937	Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.	J Clin Oncol	2016
25135711	Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Children's Oncology Group.	Pediatr Radiol	2015
25845370	Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2.	Cancer	2015
26304882	Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration.	J Clin Oncol	2015